Agoracom Blog

The Roundup – @Novamind_Inc $ $NVMDF $ $MMED $ $ $CMPS $

Posted by AGORACOM-JC at 8:56 AM on Saturday, April 24th, 2021

A weekly summary of Novamind news and media

FEATURES April 23, 2021

Dr. Reid Robison on the Science of Psychedelics

Leafy interviews Novamind’s CMO about how these compounds influence our mind on a molecular level.

FEATURES April 21, 2021

Why Merck Chose Novamind to Lead a Groundbreaking Study

Our CEO and CMO spoke with Streetwise Reports about how Cedar Clinical Research is positioned to develop a new option for treatment-resistant depression.

OPINION April 21, 2021

How Modern Psychedelics Began with a Bike Ride

On April 19, 1943, chemist Albert Hofmann took .00005 teaspoons of LSD. As he rode his bicycle home, he realized that the world had just changed. By Novamind CMO, Dr. Reid Robison and Kirsten Hirst.

View all media

Novamind Collaborates with Center for Change

April 21, 2021

Novamind Presented at the Planet MicroCap Virtual Event on April 22, 2021

April 19, 2021

Novamind Increases Strategic Investment in Bionomics

April 13, 2021

View all press releases

Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction

More Americans died from drug overdoses in 2020 than ever before. As psychedelic-assisted treatment options approach mainstream medicine, Time looks at ibogaine as a way to treat addiction like few treatments can.

Psychedelic Drug Worked As Well as Common Antidepressant, Small Trial Finds

Psilocybin works. Researchers in London released findings from a phase 2 trial indicating that a couple of doses of psilocybin may treat depression as well as one of the most commonly prescribed antidepressants. More research is required but leaders of the study were surprised with the outcome.

         Follow @novamind_inc on Instagram

Tags: , , ,

Comments are closed.